Stocker 2007.

Methods	DURATION OF INTERVENTION: 24 weeks DURATION OF FOLLOW‐UP: 24 weeks RUN‐IN PERIOD: none LANGUAGE OF PUBLICATION: English
Participants	WHO PARTCIPATED: type 2 diabetes patients with suboptimally controlled diabetes mellitus INCLUSION CRITERIA: between 21 and 80 years of age, with a glycosylated hemoglobin level above 7.0% during treatment with either diet modification or sulfonylurea monotherapy EXCLUSION CRITERIA: known inflammatory diseases (including inflammatory bowel disease, vasculitis, and rheumatologic disease), insulin use, corticosteroid use, an infection within 1 month of enrollment, glomerular filtration rate < 60 ml/min, pregnancy, known history of myocardial infarction or congestive heart failure, secondary diabetes (including Cushing’s syndrome and acromegaly), hypersensitivity to metformin or rosiglitazone, or a history of carotid endarterectomy DIAGNOSTIC CRITERIA: not stated CO‐MORBIDITIES: known cardiovascular disease [no (%)] I1: 2 (4.4%) C1: 3 (6.4%) CO‐MEDICATIONS: statin use [no (%)]: I1: 24 (53.3%) C1: 23 (48.9%) aspirin use [no (%)] : I1: 21 (46.7%) C1: 28 (59.6%) beta‐blocker use [no (%)]: I1: 8 (17.8%) C1: 7 (14.9%) calcium‐channel blocker use [no (%)]: I1: 6 (13.3%) C1: 13 (27.7%) angiotensin receptor blocker use [no (%)]: I1: 2 (4.4%) C1: 0 (0%) ACE inhibitor use [no (%)]: I1: 23 (51.1%) C1: 30 (63.8%) sulfonylurea use [no (%)]: I1: 34 (75.6%) C1: 34 (72.3%)
Interventions	NUMBER OF STUDY CENTRES: 1 COUNTRY/ LOCATION: USA SETTING: Diabetes Institute of theWalter Reed Army Medical Center, Washington DC, USA INTERVENTION (DOSE/DAY): rosiglitazone 4 mg o.d. CONTROL (DOSE/DAY): metformin 850 mg b.i.d. TREATMENT BEFORE STUDY: diet modification or sulfonylurea monotherapy TITRATION PERIOD: other concurrent therapies (sulfonylurea, antihypertensive, or statin medications) were continued at stable doses during the study nutrition counseling and diabetes education was offered to all participants at enrollment, in addition to their study medication
Outcomes	PRIMARY OUTCOMES: change in C‐reactive protein (CRP) levels after 24 weeks between the metformin and rosiglitazone treatment groups SECONDARY OUTCOMES: the predefined secondary end point was the change in mean and maximal CIMT of the common carotid artery further outcomes: FPG, HbA1c, lipids, weight, carotid intima media thickness (CIMT)
Notes	AIM OF STUDY: to compare the effects of rosiglitazone and metformin on C‐reactive protein (CRP) and carotid intima media thickness (CIMT)
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear